AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01434589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STICA Intervention
Description: Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
Study NCT02047136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group (on low histamine diet)
Description: 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
Study NCT02047136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Well-balanced diet
Description: Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
Study NCT02065167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured autologous Mesenchymal Cells
Description: Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
Study NCT00753831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aurosling
Description: Silicon rod to be used in frontalis suspension surgery
Study NCT04596020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)
Description: Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
Study NCT04596020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)
Description: Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
Study NCT04568395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCIG
Description: Use a TCIG
Study NCT04568395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG
Description: Use an ECIG
Study NCT04568395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham control
Description: Use a sham control (empty ECIG)
Study NCT03422419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
Study NCT03422419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
Study NCT03422419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: transjugular intrahepatic portosystemic shunt deployment
Study NCT04613154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesiumcitrate
Description: Magnesiumcitrate 250 mg, Apoteket AB, Sweden
Study NCT04613154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ester-c
Study NCT01752660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
Study NCT01752660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
Study NCT01752660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
Study NCT01131520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention
Description: This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
Study NCT01131520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselor delivered brief intervention
Description: This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
Study NCT01499784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: behavioral modification and pelvic floor muscle training
Study NCT01073267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEBT
Description: Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
Study NCT00513110 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AMPD1 polymorphism
Description: Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
Study NCT00513110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine infusion
Description: Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
Study NCT00513110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Endotoxin 2ng/kg combined with saline infusion (0.9%)
Study NCT04000789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
Study NCT04000789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
Study NCT00427349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
Study NCT00427349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
Study NCT02026921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
Study NCT02026921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Study NCT02941705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Derived Cells
Description: patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
Study NCT02941705 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Control Arm
Description: patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
Study NCT01460199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-499
Description: 3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)
Study NCT01460199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study NCT03946137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Therapy
Description: The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
Study NCT03946137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Hygiene
Description: Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
Study NCT02324855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy plus usual care
Description: Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
Study NCT02437864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via nasal cannula
Study NCT01553136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: 0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Study NCT01553136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Study NCT04350528 — intervention group
Intervention type: DRUG
Intervention: Chlorpromazine or Pentobarbital
Description: Sedation
Study NCT02768090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Patch
Description: Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
Study NCT01058070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torax Medical, Inc. LINX Reflux Management System
Description: Implantable device, Magnetic Esophageal Sphincter
Study NCT04288986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep Achieving
Description: The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
Study NCT02428712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FORE8394
Study NCT03877536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Description: Participants will receive 1 tablet per day throughout study duration (96 weeks).
Study NCT02198443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)
Description: (TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
Study NCT02198443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
Description: Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
Study NCT04647877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin cream
Description: Phenytoin cream to be applied on the neuropathic pain area
Study NCT04647877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream to be applied on the neuropathic pain area
Study NCT02822885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
Study NCT04310085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Description: artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
Study NCT04310085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-DVI Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study NCT01550861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro maturation
Description: Maturation of immature oocytes in the laboratory following oocyte retrieval
Study NCT01550861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polar Body Biopsy with preimplantation genetic screening
Description: Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
Study NCT03112889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
Study NCT03454802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising
Description: See above
Study NCT04752176 — intervention group
Intervention type: DEVICE
Intervention: ØREBLUE® Method
Description: The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence.
Study NCT03852862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus plane block and paravertebral block
Description: Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
Study NCT03852862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
Study NCT01124903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
Study NCT02384902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low GI
Description: All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
Study NCT02384902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional diet
Description: All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
Study NCT01271192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection and adjuvant therapy
Description: Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Study NCT01271192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant followed by operation
Description: Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV
Study NCT03184077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laceration Repair with Polyglactin 910
Description: Polyglactin 910 suture for laceration repair
Study NCT03184077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laceration Repair with poliglecaprone 25
Description: poliglecaprone 25 suture for laceration repair
Study NCT03574870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable sensor
Description: A commercially-available wearable fitness sensor
Study NCT02813278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: simo decoction
Description: Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
Study NCT02813278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gum chewing
Description: Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
Study NCT06348485 — intervention group
Intervention type: OTHER
Intervention: Patients without massive nasal bleeding
Description: No event of massive nasal bleeding after curative radiotherapy
Study NCT06348485 — intervention group
Intervention type: OTHER
Intervention: Patients with massive nasal bleeding
Description: Any event of massive nasal bleeding after curative radiotherapy
Study NCT01982474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen extract
Description: Grass pollen extract injected intralymphatically q 4 weeks x 3
Study NCT01982474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline injected intralymphatically q 4 weeks x 3
Study NCT04410588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl + Topical Levobupivacaine
Description: in nasal packing
Study NCT04410588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: in nasal packing
Study NCT02604953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Short Duration Transient Visual Evoked Potential (SDtVEP)
Description: Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
Study NCT02604953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern electroretinogram (PERG)
Description: Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
Study NCT00823849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
Study NCT00823849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: 250 mg Bid, PO after breakfast and dinner.
Study NCT00823849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol+Probucol
Study NCT00823849 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: Routine treatment
Study NCT03480568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 MG/ML [Praluent]
Description: Cholesterol-lowering therapy
Study NCT00841204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally
Study NCT00841204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inactive agent
Study NCT00841204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00841204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00784290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orantinib (TSU-68)
Description: 200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
Study NCT01212653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi
Description: Golimumab 50mg monthly
Study NCT01212653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9ml sodium chloride
Description: 0.9ml sodium chloride
Study NCT00820950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream 0.5%